pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,317 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT927Endpoints716BioPharma Dive274onclive165BioSpace162Fierce Biotech154globenewswire health73raps
therapy area
allOncology5440Rare Disease1159Cardiology988Hematology891Immunology838Pulmonology715Vaccines
  • States urged to use low-cost, scalable outreach for Medicaid enrollees facing 2027 eligibility changes
    States must begin notifying Medicaid beneficiaries about upcoming eligibility changes by September, as required by the One Big Beautiful Bill Act of 2025. The changes, set to take effect in 2027, i…
    STAT · 1d agoNeutral↗ source
  • Aspo Oyj announces upcoming leadership changes scheduled for August 10, 2026
    Aspo Oyj, a Finnish specialty chemicals company, issued a brief notice indicating that it will implement leadership transactions. The announcement specifies that the changes will take effect on Au…
    globenewswire health · 1d agoNeutral↗ source
← prev
page 4 of 93
next →
55
fda recalls36
fda medwatch25
fda press24
670
Psychiatry & CNS645
Endocrinology & Metabolism327
Ophthalmology326
Pain309
Infectious Disease301
Aspo Plc reports managers' transactions on August 10, 2026
Aspo Plc disclosed that its managers executed transactions on August 10, 2026, as recorded in a filing. The filing does not provide details about the nature, size, or parties involved in the trans…
globenewswire health · 1d agoNeutral↗ source
  • Sanofi reports shortages of Myozyme and Nexviazyme for Pompe disease after FDA manufacturing warning
    Sanofi has warned that supplies of two medicines used to treat Pompe disease are running low. The company notified patient groups and physicians in the United States and Europe that the shortage af…
    STAT · 1d agoRegulatoryNegative↗ source
  • Weekly roundup: Experts debate China biotech work ethic and a stalled megamerger
    The Endpoints News team hosted a panel of industry experts in Cambridge, Massachusetts, to examine the future of biotech in China. Participants highlighted concerns about the country’s work ethic a…
    Endpoints · 3d agoNeutral↗ source
  • Replimune secures FDA approval for Tudriqev, eyes $1.3 bn peak sales in advanced melanoma
    Replimune announced FDA approval of its therapy Tudriqev for patients with advanced melanoma who have progressed after PD-1 treatment. Analysts at BMO Capital Markets project the drug could genera…
    BioSpace · 4d agoApprovalPositive↗ source
  • Revolution Medicines sees strong demand for pancreatic cancer drug daraxonrasib under compassionate use
    Revolution Medicines reports that more than 2,000 patients have received its pancreatic cancer candidate daraxonrasib through a compassionate use program. The company says the drug has been distri…
    BioPharma Dive · 4d agoPositive↗ source
  • Bristol Myers Squibb expands Nvidia partnership to build most powerful AI supercomputer for drug discovery
    Bristol Myers Squibb announced an expanded partnership with Nvidia that will give it the most powerful and energy-efficient Nvidia infrastructure owned by a life-science company. Nvidia says the p…
    BioPharma Dive · 4d agoDealPositive↗ source
  • Replimune secures FDA accelerated approval for melanoma therapy Tudriqev
    Replimune announced that the FDA has granted accelerated approval to its melanoma therapy RP1, marketed as Tudriqev, after two earlier rejections and a third expedited review. The decision reflects…
    STAT · 4d agoApprovalPositive↗ source
  • Senate introduces BINSA bill to tighten review of China biotech and pharma transactions
    The U.S. Senate has introduced the Biotech Innovation and National Security Act (BINSA), a bill that would tighten oversight of biotech and pharmaceutical transactions involving China. The proposa…
    Endpoints · 4d agoRegulatoryNeutral↗ source
  • FDA schedules September advisory panel to review Grail's cancer test after trial miss
    The FDA announced it will hold an advisory committee meeting in September to examine Grail's multi‑cancer early detection test. The test recently failed to meet its primary endpoint in a large, ra…
    Endpoints · 4d agoRegulatoryNeutral↗ source
  • Biopharma job postings rise 15% in Q2 as layoffs fall and M&A activity picks up
    The Q2 2026 BioSpace report shows a strengthening biopharma job market, with more openings and fewer layoffs compared with the prior year. Job postings on BioSpace were up 15% year-over-year and 1…
    BioSpace · 4d agoPositive↗ source
  • Intellia identifies HLA allele linked to severe liver enzyme spikes in ATTR gene therapy
    In November 2025, a patient died after receiving Intellia Therapeutics' investigational gene silencer for transthyretin amyloidosis, prompting a safety review of the company’s ATTR gene therapy pro…
    BioSpace · 4d agoRegulatoryNeutral↗ source
  • Latigo Biotherapeutics raises $345.6M in IPO to fund non-opioid pain drug pipeline
    Latigo Biotherapeutics, a Los Angeles-based biotech focused on non-opioid ion-channel-blocking pain therapies, completed an initial public offering on Thursday. The company sold 19.2 million share…
    BioPharma Dive · 4d agoDealPositive↗ source
  • BlossomHill and Latigo close IPO week with $496 million raised
    BlossomHill Therapeutics, a cancer‑focused biotech, completed its initial public offering this week. Latigo, a company developing non‑opioid pain treatments, also went public at the same time. To…
    Endpoints · 4d agoDealPositive↗ source
  • Active shooter incident forces CDC staff to shelter in place, highlighting ongoing threats to public health workers
    On August 8, 2025, the author was working in an office at the Centers for Disease Control and Prevention when a series of loud bangs sounded outside. A laboratory director reported that a neighbori…
    STAT · 4d agoNegative↗ source
  • NIH to restrict Pathways to Independence grants to U.S. citizens and permanent residents
    The National Institutes of Health announced plans to limit eligibility for its “Pathways to Independence” award to U.S. citizens, permanent residents, and non‑citizen nationals. The change would ba…
    STAT · 4d agoRegulatoryNegative↗ source
  • Johnson & Johnson’s Global Chair of Innovative Medicine Jennifer Taubert Announces Retirement
    Jennifer Taubert, who leads Johnson & Johnson Innovative Medicine worldwide, has said she will step down from her role later this year. The company indicated that Tom (last name not disclosed) wil…
    Endpoints · 4d agoNeutral↗ source
  • BioMarin halts development of BMN401 enzyme therapy after mixed Phase 3 results
    BioMarin announced it will stop work on BMN401, an enzyme replacement therapy aimed at treating ENPP1 deficiency, a rare genetic disorder. The decision follows a Phase 3 trial that produced mixed…
    Endpoints · 4d agoNegative readoutNegative↗ source
  • Pfizer exec says China's biotech growth will decelerate as firms hit R&D frontier
    Andrew Baum of Pfizer told Endpoints News that China's rapid biotech progress is expected to slow as companies move into more advanced research and development. He explained that as Chinese firms…
    Endpoints · 4d agoNeutral↗ source
  • Eli Lilly and Novo Nordisk win dismissal of antitrust suit by compound pharmacy
    A federal judge has thrown out an antitrust lawsuit filed by a compound pharmacy against Eli Lilly and Novo Nordisk. The decision clears the two companies of the alleged wrongdoing and removes a le…
    STAT · 4d agoRegulatoryNeutral↗ source
  • Boston-born biotech founder Felix Wong launches AI-driven startup in California
    Felix Wong grew up near Boston, earned two degrees at Harvard and completed a post-doc at MIT before launching his biotech company in California. His startup applies artificial intelligence to ide…
    STAT · 4d agoNeutral↗ source
  • Third gender-affirming clinic settles with DOJ as Senate moves to hold Fauci in contempt
    A third clinic that provides gender-affirming services reached a settlement with the Department of Justice, ending a federal investigation into alleged civil-rights violations. The agreement inclu…
    STAT · 4d agoRegulatoryNeutral↗ source
  • Vistagen’s anxiety nasal spray fails to outperform placebo in Phase 2 study
    Vistagen reported results of its Phase 2 trial of the investigational nasal spray fasedienol for social anxiety disorder. The study enrolled 61 patients who were randomly assigned to receive a sin…
    BioSpace · 4d agoNegative readoutNegative↗ source
  • AI will further erode physician autonomy, says former surgeon
    Frances Mei Hardin, a former ENT surgeon and consultant, argues that artificial intelligence will not increase doctors' independence but will further reduce it. She points out that the same top-do…
    STAT · 4d agoNegative↗ source